ReviewEuropean respiratory review : an official journal of the European Respiratory Society2022
Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Review in European respiratory review : an official journal of the European Respiratory Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Pooled it
- HYAL3 as a therapeutic target for pulmonary arterial Hypertension-Cardiomyopathy comorbidity: an integrative analysis combined with machine learning and SHAP value interpretation.Frontiers in pharmacology · 2026Article
- Mechanism and Treatment of Right Ventricular Failure Due to Pulmonary Hypertension in Children.Children (Basel, Switzerland) · 2025Review
- Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD): Back to the Future.Advances in therapy · 2025Review
- Right heart reverse remodeling:International journal of cardiology. Congenital heart disease · 2025Article
- Contemporary treatment of right ventricular failure.JHLT open · 2025Review
- Novel Therapies for Right Ventricular Failure.Current cardiology reports · 2025Review
- Diagnosis model for assessing chronic thromboembolic pulmonary hypertension in high-altitude pulmonary embolism patients: a machine learning approach.Frontiers in medicine · 2025Article
- Successful management of HeartMate 3 in a patient with arrhythmogenic right ventricular cardiomyopathy.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2024Article
- The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Modulating NO-GC Pathway in Pulmonary Arterial Hypertension.International journal of molecular sciences · 2023Review
- Article
- Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.Current heart failure reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 13 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH, successful treatments should lead to improvements in RV parameters. Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of PAH and inoperable or persistent/recurrent CTEPH after pulmonary endarterectomy. This review examines the current evidence showing the effect of riociguat on the right ventricle, with particular focus on remodelling, function and structural parameters in preclinical models and patients with PAH or CTEPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.